Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly used to treat several malignancies, with the most common adverse event being cutaneous toxicity. We report the case of a 68-years-old man with stage IV non-small cell lung cancer treated with nivolumab who developed a pruritic, lichenoid eruption refractory to treatment with topical or systemic steroids, who was started on narrow band ultraviolet B therapy which resolved the reaction.
|Original language||English (US)|
|Journal||Frontiers in Oncology|
|State||Published - Sep 25 2018|
- PD-1 inhibitor
- non-small cell lung cancer
ASJC Scopus subject areas
- Cancer Research